[ACE inhibition and atherogenesis].
Schölkens
B A
BA
Aventis Pharma Deutschland GmbH, Disease Groups Research, Bldg H 821, 65926 Frankfurt/Main.
Landgraf
W
W
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors